Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer

PURPOSE: Assess efficacy and toxicity of gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, added to, and in maintenance after, concurrent chemoradiotherapy (CCRT) in locally advanced head and neck cancer (LA-HNC) and correlate outcomes with EGFR gene copy number alterations. PATIENTS...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Cohen, Ezra E.W., Haraf, Daniel J., Kunnavakkam, Rangesh, Stenson, Kerstin M., Blair, Elizabeth A., Brockstein, Bruce, Lester, Eric P., Salama, Joseph K., Dekker, Allison, Williams, Rosalyn, Witt, Mary Ellyn, Grushko, Tatyana A., Dignam, James J., Lingen, Mark W., Olopade, Olufunmilayo I., Vokes, Everett E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2010
Soggetti:
Original Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2903330/
https://ncbi.nlm.nih.gov/pubmed/20498391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.27.0397
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi